FibroGen, Inc.

NasdaqGS:FGEN 株式レポート

時価総額：US$68.7m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

FibroGen マネジメント

マネジメント 基準チェック /24

FibroGen'sの CEO はThane Wettigで、 Jul2023年に任命され、 の在任期間は 1 年未満です。 の年間総報酬は$ 3.64Mで、 15.7%給与と84.3%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.19%を直接所有しており、その価値は$ 200.83K 。経営陣と取締役会の平均在任期間はそれぞれ2.9年と5.3年です。

主要情報

Thane Wettig

最高経営責任者

US$3.6m

報酬総額

CEO給与比率15.7%
CEO在任期間less than a year
CEOの所有権0.2%
経営陣の平均在職期間3yrs
取締役会の平均在任期間5.3yrs

経営陣の近況

Recent updates

FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward

Jun 06

Pamrevlumab And Roxadustat: Evaluating FibroGen's Future Amid Financial Strains

May 28

Benign Growth For FibroGen, Inc. (NASDAQ:FGEN) Underpins Stock's 28% Plummet

May 07
Benign Growth For FibroGen, Inc. (NASDAQ:FGEN) Underpins Stock's 28% Plummet

FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

Mar 22
FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise

Feb 05
There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise

FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%

Dec 22
FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%

A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)

Nov 24
A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)

Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)

Apr 18
Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

Feb 13
Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

The FibroGen, Inc. (NASDAQ:FGEN) Analysts Have Been Trimming Their Sales Forecasts

Nov 12
The FibroGen, Inc. (NASDAQ:FGEN) Analysts Have Been Trimming Their Sales Forecasts

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

Oct 09
Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

FibroGen completes patient enrollment for Roxadustat to treat anemia in patients

Aug 26

FibroGen Q2 2022 Earnings Preview

Aug 05

Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?

Jul 06
Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?

Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?

Mar 31
Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?

Time To Worry? Analysts Are Downgrading Their FibroGen, Inc. (NASDAQ:FGEN) Outlook

Mar 05
Time To Worry? Analysts Are Downgrading Their FibroGen, Inc. (NASDAQ:FGEN) Outlook

Is FibroGen (NASDAQ:FGEN) Using Debt In A Risky Way?

Dec 08
Is FibroGen (NASDAQ:FGEN) Using Debt In A Risky Way?

News Flash: 10 Analysts Think FibroGen, Inc. (NASDAQ:FGEN) Earnings Are Under Threat

Aug 12
News Flash: 10 Analysts Think FibroGen, Inc. (NASDAQ:FGEN) Earnings Are Under Threat

Downgrade: Here's How Analysts See FibroGen, Inc. (NASDAQ:FGEN) Performing In The Near Term

Jul 17
Downgrade: Here's How Analysts See FibroGen, Inc. (NASDAQ:FGEN) Performing In The Near Term

Is FibroGen A Buy Going Into Roxa AdCom?

Jul 13

CEO報酬分析

FibroGen の収益と比較して、Thane Wettig の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2024n/an/a

-US$240m

Dec 31 2023US$4mUS$573k

-US$284m

Sep 30 2023n/an/a

-US$294m

Jun 30 2023n/an/a

-US$322m

Mar 31 2023n/an/a

-US$307m

Dec 31 2022US$3mUS$535k

-US$294m

Sep 30 2022n/an/a

-US$362m

Jun 30 2022n/an/a

-US$220m

Mar 31 2022n/an/a

-US$281m

Dec 31 2021US$3mUS$510k

-US$290m

Sep 30 2021n/an/a

-US$215m

Jun 30 2021n/an/a

-US$231m

Mar 31 2021n/an/a

-US$183m

Dec 31 2020US$4mUS$263k

-US$189m

報酬と市場: Thaneの 総報酬 ($USD 3.64M ) は、 US市場 ($USD 673.68K ) の同規模の企業の平均を上回っています。

報酬と収益: Thaneの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Thane Wettig (59 yo)

less than a year

在職期間

US$3,640,829

報酬

Mr. Thane Wettig serves as Director of FibroGen, Inc. since October 2, 2023. He serves as Chief Executive Officer at FibroGen, Inc. since October 2, 2023 and served as Interim Chief Executive Officer since...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Thane Wettig
CEO & Directorless than a yearUS$3.64m0.19%
$ 131.7k
Juan Graham
Senior VP & CFO2.8yrsUS$3.09m0.065%
$ 44.6k
Christine Chung
Senior Vice President of China Operations17.5yrsUS$3.11m0.32%
$ 222.3k
Barry Berkowitz
Founder29.5yrsデータなしデータなし
John Hunter
Chief Scientific Officer3yrsデータなしデータなし
David DeLucia
Vice President of Corporate FP&A and Investor Relationsno dataデータなしデータなし
Michael Lowenstein
Chief Legal Officer8.3yrsデータなしデータなし
Tricia Stewart
Chief People Officer3.2yrsデータなしデータなし
Kirk Christoffersen
Chief Business Officer3.7yrsデータなしデータなし
Rahul Kaushik
Senior Vice President of Pharmaceutical Development2.5yrsデータなしデータなし
Elizabeth Bearby
Senior VP of Regulatoryless than a yearデータなしデータなし
Deyaa Adib
Senior VP & Chief Medical Officerless than a yearデータなし0.083%
$ 56.7k

3.0yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: FGENの経営陣は 経験豊富 であると考えられます ( 2.9年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Thane Wettig
CEO & Directorless than a yearUS$3.64m0.19%
$ 131.7k
George Martin
Chairman of Scientific Advisory Boardno dataデータなしデータなし
Suzanne Blaug
Independent Director5.1yrsUS$388.03k0.021%
$ 14.7k
Jeffrey Edwards
Independent Director8.8yrsUS$385.53k0.026%
$ 17.7k
James Schoeneck
Independent Chairman of the Board14.3yrsUS$499.58k0.082%
$ 56.3k
Gerald Lema
Independent Director6.8yrsUS$383.03k0.037%
$ 25.6k
Maykin Ho
Independent Director5.6yrsUS$375.53k0.023%
$ 16.0k
Benjamin Cravatt
Independent Director3.9yrsUS$392.55k0.021%
$ 14.1k
Aoife Brennan
Independent Director3.9yrsUS$373.03k0.020%
$ 13.6k

5.3yrs

平均在職期間

63yo

平均年齢

経験豊富なボード: FGENの 取締役会 は 経験豊富 であると考えられます ( 5.3年の平均在任期間)。